No Detail Found!

Relationship between serum CEACAM1 levels and prognosis and temozolomide chemotherapy sensitivity in patients undergoing neuroendoscopic transsphenoidal pituitary tumor resection

Author(s)
Chong Chen Ma Department of Neurosurgery, Huai'an Hospital of Huai'an City,Huai 'an City, Jiangsu Province,China
Er Ping He Department of Neurosurgery, Huai'an Hospital of Huai'an City,Huai 'an City, Jiangsu Province,China
Yue Qing Zhang Department of Neurosurgery, Huai'an Hospital of Huai'an City,Huai 'an City, Jiangsu Province,China
Yong Jing Wang Department of Neurosurgery, Huai'an Hospital of Huai'an City,Huai 'an City, Jiangsu Province,China
Chun Ming Zhu Department of Neurosurgery, Huai'an Hospital of Huai'an City,Huai 'an City, Jiangsu Province,China
Xuan Yu Department of Neurosurgery, Huai'an Hospital of Huai'an City,Huai 'an City, Jiangsu Province,China
Abstract
Pituitary tumors are common intracranial neoplasms with complex pathogenesis. Temozolomide (TMZ) has shown potential in treatment, but its efficacy and related biomarkers require further investigation. This study explores the relationship between serum CEACAM1 levels, prognosis after neuroendoscopic transsphenoidal pituitary tumor resection, and TMZ sensitivity. A retrospective analysis of 70 patients who underwent surgery from 2020 to 2022 was conducted. Patients were classified into high- and low-CEACAM1 groups. Baseline characteristics showed no significant differences (P>0.05). After six months, patients with poor prognosis had significantly higher preoperative CEACAM1 levels (P<0.05). TMZ-resistant patients also had elevated levels (P<0.05). The AUC of preoperative CEACAM1 for predicting prognosis was 0.716 (cutoff: 5857.5 pg/mL), and for TMZ resistance was 0.742 (cutoff: 6431 pg/mL). High preoperative CEACAM1 levels are associated with poor prognosis and TMZ resistance, serving as a potential biomarker to guide clinical evaluation and treatment.
Publication Details
Page(s) 165-173
Published Journal: Pakistan Journal of Pharmaceutical Sciences, Volume: 38, Issue: 1, Year: 2025

Request the full text from PASTIC

Keywords
prognosis, Temozolomide, neuroendoscopic transsphenoidal pituitary tumor resection, chemosensitivity, CEACAM1
References
Araujo-Castro M,Berrocal VR,Pascual-Corrales E .2020 .Pituitary tumors: Epidemiology and clinical presentation spectrum. Hormones (Athens), 19(2) : 145-155.
Bonneville JF,Potorac J,Beckers A .2020 .Neuroimaging of aggressive pituitary tumors. Rev. Endocr. Metab, 21(2) : 235-242.
Fiori V,Magnani M,Cianfriglia M M .2012 .The expression and modulation of CEACAM1 and tumor cell transformation. , 48(2) : 161-71.
Gheorghe G,Diaconu CC,Mambet C,Bleotu C,Ionescu VA,Diaconu CC .2024 .Comparative analysis of leptin and carcinoembryonic antigen-related cell adhesion molecule 1 plasma expression in pancreatic cancer and chronic pancreatitis patients. , 10(17) : e37410.
Götz L,Rueckschloss U,Najjar SM,Ergun S,Kleefeldt F S,Clin S .2024 .Carcinoembryonic antigen-related cell adhesion molecule 1 in cancer: Blessing or curse? Eur. , 25 : e14337.
He Y,Yuan Y,Ji L,Shu Y,Wang Z,Zhang S,Yang W,Chen M,Liu Y .2024 .Integrative analysis identifies NSUN2 as an essential coordinator for glioma malignancy and glucose metabolism. J. Gene. Med, 26(12) : e70004.
Huang YH,Yoon CH,Gandhi A,Hanley T,Castrillon C,Kondo Y,Lin X,Kim W,Yang C,Driouchi A,Carroll M,Gray-Owen SD,Wesemann DR,Drake CG,Bertagnolli MM,Beauchemin N,Blumberg RS .2024 .High-dimensional mapping of human CEACAM1 expression on immune cells and association with melanoma drug resistance. Commun. Med, 4(1) : 128.
Iglesias P,Magallón R,Mitjavila M,Rodríguez Berrocal V,Pian H,Diez JJ H .2020 .Multimodal therapy in aggressive pituitary tumors. Endocrinol. Diabetes Nutr, 67(7) : 469-485.
Jeon SH,Kang M,Jeon M,Chung Y,Kim AR,Lee YJ,Kim ES,Nam H,Park J,Lee JY,Shin EC,Seo SI,Park SH .2023 .CEACAM1 marks highly suppressive intratumoral regulatory T cells for targeted depletion therapy. Clin. Cancer Res., 29(9) : 1794-1806.
JKonieva A,Deineka V,Diedkova K,Aguilar-Ferrer D,Lyndin M,Wennemuth G,Korniienko V,Kyrylenko S,Lihachev A,Zahorodna V,Baginskiy I,Coy E,Gogotsi O,Blacha-Grzechnik A,Simka W,Kube-Golovin I,Iatsunskyi I,Pogorielov M .2024 .MXenePolydopamine-antiCEACAM1 antibody complex as a strategy for targeted ablation of melanoma. ACS Appl. Mater. Interfaces, 16(33) : 43302-43316.
Liu W .2022 .Serum Level of CEACAM1 in patients with nonsmall cell lung cancer and its clinical significance in cancer tissue. J. Healthc. Eng., 7948010 : .
Markel G,Seidman R,Cohen Y,Besser MJ,Sinai TC,Treves AJ,Orenstein A,Berger R,Schachter J .2009 .Dynamic expression of protective CEACAM1 on melanoma cells during specific immune attack. Immunology, 126(2) : 186-200.
Marrero-Rodríguez D,Taniguchi-Ponciano K,Kerbel J,Cano-Zaragoza A,Remba-Shapiro I,Silva-Román G,Vela-Patiño S,Andonegui-Elguera S,Valenzuela-Perez A,Mercado M .2023 .The hallmarks of cancer… in pituitary tumors? Rev. , 24(2) : 177-190.
Matsumoto H,Sudo R,Fujita Y,Onizawa M,Saito K,Sumichika Y,Yoshida S,Temmoku J,Matsuoka N,Asano T,Sato S,Suzuki E,Machida T,Migita K .2024 .Inhibition of CEACAM1 expression in cytokine-activated neutrophils using JAK inhibitors. BMC Immunol, 25(1) : 63.
Muturi HT,Ghadieh HE,Asalla S,Lester SG,Verhulst S,Stankus HL,Zaidi S,Abdolahipour R,Belew GD,Grunsven LA,Friedman SL,Schwabe RF,Hinds TD,Najjar SM .2024 .Conditional deletion of CEACAM1 causes hepatic stellate cell activation. Update in: Mol. Metab, 88 : 102010.
Rao V,Kumar G,Vibhavari RJA,Nandakumar K,Thorat ND,Chamallamudi MR,Kumar N MR .2023 .Temozolomide resistance: A multifarious review on mechanisms beyond O-6-Methylguanine-DNA methyltransferase. CNS Neurol. Disord. Drug Targets, 22(6) : 817-831.
Sauer N,Janicka N,Szlasa W,Skinderowicz B,Kołodzińska K,Dwernicka W,Oślizło M,Kulbacka J,Novickij V,Karłowicz-Bodalska K .2023 .TIM-3 as a promising target for cancer immunotherapy in a wide range of tumors. Cancer Immunol, 72(11) : 3405-3425.
Schwartz LH,Litière S,de Vries E,Ford R,Gwyther S,Mandrekar S,Shankar L,Bogaerts J,Chen A,Dancey J,Hayes W,Hodi FS,Hoekstra OS,Huang EP,Lin N,Liu Y,Therasse P,Wolchok JD,Seymour L JD .2016 .. RECIST 1.1-Update and clarification: From the RECIST Committee. Eur. J. Cancer, 62 : 132-137.
Southekal S,Shakyawar SK,Bajpai P,Elkholy A,Manne U,Mishra NK,Guda C .2023 .Molecular subtyping and survival analysis of osteosarcoma reveals prognostic biomarkers and key canonical pathways. Cancers (Basel), 15(7) : 2134.
Spada A,Mantovani G,Lania AG,Treppiedi D,Mangili F,Catalano R,Carosi G,Sala E,Peverelli E .2022 .Pituitary tumors: Genetic and molecular factors underlying pathogenesis and clinical behavior. J. Neuroendocrinol., 112(1) : 15-33.
Tang R,Lin W,Shen C,Hu X,Yu L,Meng T,Zhang L,Eggenhuizen PJ,Ooi JD,Jin P,Ding X,Xiao X,Zhong Y,Pt A .2023 .Single-cell transcriptomics uncover hub genes and cell-cell crosstalk in patients with hypertensive nephropathy. Int. Immunopharmacol., 111104 : .
Toader C,Bratu BG,Mohan AG,Bentia D,Ciurea AV D .2023 .Comparison of transcranial and transsphenoidal approaches in intra and suprasellar pituitary adenomas - systematic review. Acta Endocrinol (Buchar), 19(2) : 228-233.
Tritos NA,Miller KK .2023 .Diagnosis and management of pituitary adenomas: A review. JAMA, 329(16) : 1386-1398.
Veleno M,Giampietro A,Raia S,Menotti S,Tartaglione T,Gaudino S,Doglietto F,DE Marinis L,Pontecorvi A,Chiloiro S,Bianchi A .2024 .Clinical implications of the 2022 WHO classification on the multidisciplinary management of PitNETS patients. Minerva Endocrinology, 49(3) : 269-282.
Yi E,Go J,Yun SH,Lee SE,Kwak J,Kim SW,Kim HS .2024 .CEACAM1-engineered MSCs have a broad spectrum of immunomodulatory functions and therapeutic potential via cell-to-cell interaction. Biomaterials, 311 : 122667.
Yu J,Cai W,Zhou T,Men B,Chen S,Tu D,Guo W,Wang J,Zhao F,Wang Y .2024 .CEACAM1 increased the lymphangiogenesis through miR-423-5p and NFkB in non-small cell lung cancer. Biochem. Biophys. Rep, 40 : 101833.
Zhang B,Liu R,Huang H,Wang C,Yang C .2024 .Identifying CEACAM1 as a potential prognostic biomarker for basal-like breast cancer by bioinformatics analysis and in vitro experiments. J. Cancer, 15(19) : 6468-6478.
Zhao L,Li T,Zhou Y,Wang P,Luo L P .2024 .. , : .
0

Citations

0

Downloads

53

Views